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REVIEW ESSAYIdentifying Human Naïve Pluripotent Stem
Cells  Evaluating State-Specific Reporter Lines
and Cell-Surface MarkersAmanda J. Collier and Peter J. Rugg-Gunn*Recent reports that human pluripotent stem cells can be captured in a
spectrum of states with variable properties has prompted a re-evaluation of
how pluripotency is acquired and stabilised. The latest additions to the stem
cell hierarchy open up opportunities for understanding human development,
reprogramming, and cell state transitions more generally. Many of the new
cell lines have been collectively termed ‘naïve’ human pluripotent stem cells
to distinguish them from the conventional ‘primed’ cells. Here, several
transcriptional and epigenetic hallmarks of human pluripotent states in the
recently described cell lines are reviewed and evaluated. Methods to derive
and identify human naïve pluripotent stem cells are also discussed, with a
focus on the uses and future developments of state-specific reporter cell lines
and cell-surface proteins. Finally, opportunities and uncertainties in naïve
stem cell biology are highlighted, and the current limitations of human naïve
pluripotent stem cells considered, particularly in the context of
differentiation.1. Introduction
Pluripotency, the ability to form all cell lineages of the body, can
be captured in different states and form phenotypically distinct
cell types.[1–4] One of the surprises encountered by Thomson
and colleagues when they first derived human and rhesus
pluripotent stem cells (PSCs) was that the cells looked nothing
like their mouse counterparts  the morphological waymark at
the time.[5–7] This unanticipated difference would have misled
many researchers involved in the pioneering studies of the
1990s, who perhaps did not realise the cell types they had in
their tissue culture dishes. When viewed under the microscope,
human PSCs (hPSCs) grow as large, flat colonies of tightly
packed cobblestone cells, whereas mouse PSCs (mPSCs) growA. J. Collier, Dr. P. J. Rugg-Gunn
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characterisation of the newly derived cell
lines showed differential cell-surface
marker expression when compared to
mPSCs, the primate cells more closely
mimicking human embryonal carcinoma
cells, the haphazard, pluripotent cells that
grow from germ cell tumors.[5–9] Further
investigations over the following years
revealed that molecular, signaling, and
metabolic differences are also prevalent
between human and mouse PSCs.[10,11]
This has an enormous impact on estab-
lishing appropriate benchmarks for clas-
sifying cells, and also requires the
adoption of different protocols as
approaches developed for one cell type
might not be easily translated to another.
The origins of the divergent mouse and
human PSC states are obscure given that
the first PSC lines of both species werederived from embryos at equivalent developmental stages and
under the same culture conditions.[5,12,13] This observation tells
us that embryo outgrowths of mouse and human blastocysts will
default to different cell types. We now know that preimplanta-
tion-stage epiblast cells can give rise to alternative pluripotent
states depending on the culture conditions used. When mPSCs
are derived and maintained in the presence of leukaemia
inhibitory factor (LIF) and 2i (dual inhibition of MEK and GSK3)
the resultant cell lines are in a ‘naïve’ state of pluripotency and
correspond to the preimplantation epiblast.[2,14] Alternatively,
when derived in conditions containing FGF and Activin A,
epiblast stem cells (EpiSCs) are formed, which are considered to
represent a ‘primed’ state of pluripotency.[15,16] EpiSCs can be
obtained from either preimplantation epiblast cells,[17] or more
commonly, from the postimplantation epiblast tissue that forms
a day or two later in development.[15,16,18] Although both naïve
and primed mPSCs can self-renew and are pluripotent, there are
substantial transcriptional, epigenetic and metabolic differences
that contribute to the classification of pluripotent states.[19–21]
The majority of human PSC lines exhibit properties that
resemble primed, mouse EpiSCs, indicating that the conven-
tional culture conditions used to derive hPSCs are unable to hold
the cells in a preimplantation state of development. Comparison
to transcriptional profiles collected from primate embryos at
different developmental stages support the similarity of hPSCs
to postimplantation-stage epiblast cells.[22] This observation is
reinforced by the considerable gene expression and epigeneticAuthors. BioEssays Published by WILEY Periodicals, Inc.
www.advancedsciencenews.com www.bioessays-journal.comdifferences between hPSCs and preimplantation-stage human
epiblast cells.[23–28]
The divergences in PSC states between species, and also
between hPSCs and the preimplantation epiblast cells from
which they are derived, present an exciting avenue to capture
hPSCs in a naïve state of pluripotency.[29–31] Naïve hPSCs offer
an important model to study human preimplantation biology
including the regulation of lineage decisions, responsiveness to
signaling activities, and how developmental progression is
compromised by genetic and epigenetic errors. Moreover, naïve
pluripotent cells would open up the investigation of how
pluripotent states are controlled, and could provide practical
advantages such as increased clonal efficiency, growth rates and
recombination frequencies compared to primed PSCs. There
have been exciting advances towards obtaining naïve hPSCs,
which have accelerated over the past 3 years. Here, we aim to
review recent progress with a focus on 1) hallmarks of naïve
hPSCs; 2) approaches to derive naïve hPSCs; and 3) methods to
track human pluripotent states and isolate nascent naïve hPSCs.
We then highlight current gaps in our understanding of naïve
pluripotency, particularly in the context of uses and limitations of
naïve hPSCs, and finally suggest areas for future study.2. A Molecular Framework to Guide Human
Pluripotent State Characterization
Assigning molecular criteria to define human pluripotent states
is difficult as there is a shortage of information on human
embryos due to the ethical and practical restrictions associated
with this line of research. Current efforts to derive and
characterise naïve hPSCs are based on knowledge gained from
mouse studies and this will often be inaccurate due to the
differences between species. Recent molecular and phenotypic
investigations of human and primate embryos are beginning to
provide an important set of waymarks. Based on these initial
studies, several characteristics of naïve human pluripotency have
been proposed and collectively provide a helpful framework with
which to evaluate human cells (Figure 1 and Table 1).[26,32]2.1. Transcriptional Signatures of Naïve hPSCs Align to
Human Preimplantation Epiblast
Global transcriptome analyses of human embryos have delivered
a rich resource to extract lineage–specific and developmental
stage–specific gene expression profiles, and provide biologically
relevant benchmarks for assessing hPSCs.[23,24,28,33] A cohort of
genes enriched in human preimplantation epiblast cells is highly
expressed in naïve but not in primed hPSCs (Figure 1).[28] There
is a considerable range in the expression levels of naïve-
associated genes when comparing between various naïve hPSCs
lines derived in different conditions, indicating that some
conditions are better than others at recapitulating the transcrip-
tional programmes of human epiblast cells.[25–28,34] Additionally,
genes such as KLF4 and TFCP2L1 are sensitive to perturbation
only in naïve hPSCs, suggesting a rewiring in gene regulatory
circuitries and dependencies has occurred between naïve and
primed pluripotent states.[35] This is further supported byBioEssays 2018, 40, 1700239 1700239 (2 of 12)evidence of cell-type-specific enhancer activity and connectivity
at genes that include the transcription factors POU5F1
(encoding OCT4) and KLF4; regulatory switches that can be
used to readout pluripotent state when hitched to a reporter
gene.[36,37]2.2. Resetting of DNA Methylation Levels and X-
Chromosome Activity are Hallmarks of Naïve hPSCs
The epigenome undergoes global remodeling as cells transition
from pre- to postimplantation development, and these changes
can be used to define pluripotent state. DNA hypomethylation
is a property of human and mouse preimplantation embryos,
and provides an important hallmark of naïve pluripotency.
Transient loss of DNA methylation during early development
resets the epigenome, and might also facilitate developmental
plasticity before the onset of cell differentiation.[38,39] As for the
transcriptional readouts, the extent of DNA hypomethylation
varies between different naïve hPSC lines (Table 1). Cells
maintained in some naïve-like formulations have global DNA
methylomes close to 70%, which is the same level as in primed
hPSCs.[27,40] In contrast, naïve hPSCs maintained in other
conditions have a global DNA methylation level of 30%,
which is broadly similar to the human blastocyst at
20–40%.[26,27,34,38,41] Despite this similarity at the global level,
there are substantial differences in the distribution of
methylated CpG sites across the genomes of naïve hPSCs
and human embryos. For example, imprinted gene control
regions are methylated in the embryo but are hypomethylated
in naïve hPSCs.[26,27] This difference might be due to the
prolonged maintenance of naïve hPSCs in conditions that
suppress the DNA methylation machinery, as has recently been
suggested in mPSCs.[38] Current models in naïve mPSCs
propose that this suppressive effect is mediated by continuous
inhibition of MEK,[42,43] although there are MEK inhibitor-
containing conditions that can maintain naïve-like hPSCs
without the loss of global DNA methylation or imprints
(Table 1).[27,40] This observation suggests that either the precise
level of MEK suppression is crucial or the presence of other
factors are additionally involved in controlling DNA methyl-
ation in pluripotent cells.
A further epigenetic hallmark to discriminate between naïve
and primed hPSCs is the X-chromosome inactivation status in
female cells (Figure 1). Until recently, it was assumed that
similar mechanisms might govern X-chromosome dosage
compensation in mouse and human, however a number of
distinct differences have become apparent that are related to the
order, timing of events andmolecular control of this process. The
first difference is the absence of paternal X-chromosome
silencing during human preimplantation development.[44]
Instead, there appears to be a gradual dampening of expression
from both X-chromosomes to halve the transcriptional output in
human embryos.[33] The second difference relates to the control
of X-chromosome inactivation. In mouse embryos, induction of
the long, non-coding RNA (lncRNA) Xist triggers X-chromosome
silencing in cis. In contrast, XIST is expressed from both X-
chromosomes in human, female cells without triggering
inactivation.[33,45,46] It has been proposed that the presence of© 2018 The Authors. BioEssays Published by WILEY Periodicals, Inc.
Figure 1. Hallmarks associated with naïve and primed human pluripotent states. (1) The core pluripotency transcription factors OCT4, SOX2, and
NANOG are expressed in naïve and primed hPSCs, whereas several other transcription factors are uniquely detected in each cell type. (2) Naïve hPSCs
display global DNA hypomethylation compared to primed hPSCs. (3) Naïve hPSCs have two active X-chromosomes in female hPSCs, indicated by
biallelic X-linked gene expression including XIST and XACT, and localised depletion of the repressive histone mark H3K27me3. (4) Naïve hPSCs exhibit
preferential activity of the OCT4 distal enhancer, whereas primed hPSCs use the proximal enhancer. (5) The distribution of H3K27me3 differs between
naïve and primed hPSCs, with a reported reduction of H3K27me3 levels in naïve hPSCs at >3000 Polycomb-associated gene promoters. (6) Identified
cell-surface markers can be used to distinguish between naïve and primed hPSCs.
www.advancedsciencenews.com www.bioessays-journal.coma primate-specific lncRNA, XACT, acts as an antagonist of XIST
by preventing XIST-mediated X-chromosome silencing.[45]
XACT may account for some of the differences observed
between mouse and human embryos, where the detection of
XIST in preimplantation human embryos does not indicate X-
chromosome inactivation. Conventional primed hPSCs typically
have one inactive and one active X-chromosome in female cells,
which infers a progression to the post-implantation stage.BioEssays 2018, 40, 1700239 1700239 (3 of 12)Strikingly, cells maintained in several naïve hPSC formulations
can recapitulate aspects of the preimplantation X-chromosome
status, including the presence of two active X-chromosomes,
whereas other conditions do not appear to robustly reactivate
the silenced X-chromosome (Table 2). In conclusion, the
X-chromosome status in female cells can be used as an
additional hallmark to assess the relative similarity to the
preimplantation embryo.© 2018 The Authors. BioEssays Published by WILEY Periodicals, Inc.
Table 1. Characteristics of naïve and primed states of pluripotency.
Attribute Naïve state Primed State Presence of naïve state attributes in studies reporting the conversion of primed to naïve hPSCs
In vivo
terminology
Preimplantation
epiblast
Postimplantation
epiblast
Hanna[47] Gafni
NHSM[40]
Chan
3iL[48]
Ware[50] Theunissen
5iLAF[37] 5iLA[26]
Takashima
t2iLþPKCi[35]
Chen[49] Duggal[57] Qin[58] Guo
t2iLþPKCi[34]
Appearance Domed (@) Flat (X) @ @ @ @ @ @ @ @ @ @
Single cell
survival
High (@) Low (X) @ @ @ @ @ @ @ @ @ @
Methylation
(global CpG)
Low (30%) High (80%) – High – – Low Low Med Med – Low
H3K27me3
levels
Low at promoters High at
promoters
– Low Low Low Low – Low – – –
OCT4
enhancer
Distal (@) Proximal (X) @ @[40]
X[37]
–[48]
X[37]
@[50]
X[37]
@[37] @ @ – – @
Metabolism Oxidative
phosphorylation
(@)
Glycolytic (X) – – – @ – @ – – – –
@, presence of naïve state attribute; X, absence of naïve state attribute; , attribute not examined.
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hPSCs in a Preimplantation-Like State
By benchmarking to the hallmarks of naïve pluripotency and
guided by earlier mouse studies, several groups have reported
the development of cell culture conditions that are capable of
stabilising hPSCs in a naïve-like state.3.1. Varying Growth Conditions Induce a Spectrum of
Human Pluripotent States
Ectopic expressionof the pluripotency transcription factorsOCT4,
KLF4, and KLF2 in combination with 2i/LIF generated human
cells with several predicted naïve PSC characteristics.[47] However,Table 2. X-chromosome status associated with naïve and primed hPSCs.
X-chromosome
status
Naïve
state
Primed
state Hanna[47]
Gafni
NHSM[40] RSeT[45,64] W
X-linked gene
expression
Biallelic Monoallelic
from Xa
[45,64]
XIST expression Biallelic Monoallelic
from Xi
[40,64]
[45,64]
XACT expression Biallelic Monoallelic
from Xa
[45,64]
[45,64]
H3K27me3
X-chromosome
foci
Absence Enrichment
over Xi
[40]
[64]
Xa, active X-chromosome; Xi, inactive X-chromosome.
Note that Chan et al.,[48] Duggal et al.,[57] and Qin et al.[58] did not report X-chromos
BioEssays 2018, 40, 1700239 1700239 (4 of 12)the withdrawal of transgene expression induced rapid cell
differentiation, providing the key demonstration that 2i/LIFalone
is insufficient tomaintainhPSCs inanaïvestate,unlike inmPSCs.
Since then, stable, transgene-free naïve-like hPSCs have been
described in multiple studies.[40,48–50] All culture formulations
are based on 2i/LIF supplemented with additional components
(Figure 2 and Table 3). The resultant cells displayed changes in
some of the predicted properties of naïve hPSCs, including
increased single-cell cloning efficiency,[40,48] higher rates of
homologous recombination[40] and the upregulation of several
naïve-associated genes.[48] Interestingly, impaired self-renewal
and morphological changes were reported when the naïve-like
hPSCs were grown without LIF or with inhibitors of the LIF
pathway, confirming the acquisition of LIF dependency to
maintain the cell lines.[48,50] In contrast, exogenous LIF is notare[50]
Theunissen
5iLAF[37,60] 5iLA[26,45]
Takashima
t2iLþPKCi[35,45,60,64] Chen[49]
Guo
t2iLþPKCi[34]
[26,45,60] [64]
[45,60,64]
[45]
[45,60]
[26,37,45,60]
[45,60,64]
[45,60,64]
[45,60,64]
[45]
[45,60]
[45,64]
[45,64]
over Xa [60] [35,45,64]
[64]
ome status.
© 2018 The Authors. BioEssays Published by WILEY Periodicals, Inc.
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Figure 2. Signaling pathways in naïve and primed human pluripotent states. The different cocktails of inhibitors and growth factors used to induce naïve
pluripotency are a likely cause of the reported spectrum of pluripotent states. It is important to note that additional pathways that are not highlighted
here are also likely to be involved. Moreover, many of the chemical inhibitors used will non-specifically inhibit additional targets, even extending to
components of different signaling pathways. Dashed lines indicate likely indirect effects.
www.advancedsciencenews.com www.bioessays-journal.comessential for conventional primed hPSC self-renewal.[51,52]
Downstream of LIF binding, the activation of STAT3 is both
necessary and sufficient for the maintenance of mPSC
self-renewal,[53] partly through maintaining Klf4 and Tfcp2l1
expression,[54–56] and initial evidence points to a similar role in
naïve-like hPSCs.[48] Furthermore, the reinforcement of STAT3
in the presence of 2i/LIF can facilitate primed to naïve-like
reprogramming of hPSCs, and in this way, we can begin to
understand the crosstalk between different signaling pathways
(Figure 2 and Table 3).[49,50] To identify additional factors that
might stabilise naïve hPSCs, other media formulations have
been developed that include inhibitors of PKA and HIPPO
signaling[57–59] (Table 3). These cells have not been fully
characterised, particularly for epigenetic hallmarks, and it will
be interesting to see how they compare against the others
(Table 1).
Gene network analyses and transcriptional comparisons on a
subset of cell lines show that there is a substantial variability
between the putative naïve hPSC cultures described above,
resulting in a spectrum of cell phenotypes that is likely to be
driven by their different growth conditions.[25] For many of these
cell lines, the shift in transcriptional profiles towards a
preimplantation state is rather minor,[25,28,40,48,50] and in some
instances might be driven by the induction of a small cohort of
metabolic genes rather than robust changes in regulatory
circuitry.[25] There is also conflicting data for some of the above
growth conditions with evidence that the cells are unable to
activate a naïve-specific OCT4 reporter line, thereby unfulfilling
this molecular hallmark (Table 1).[37] Additionally, for some of
the conditions, female cells were reported to have reactivated
their previously silenced X-chromosome, which would be a
feature of naïve pluripotency (Table 2).[40,50] The data presented
showed an absence of XISTand H3K27me3 foci in the naïve-like
hPSCs (Table 2), which at the time was thought to indicate theBioEssays 2018, 40, 1700239 1700239 (5 of 12)presence of two active X-chromosomes. However, we now know
that XIST is expressed from active X-chromosomes in human
blastocysts and naïve hPSCs,[45,60] and that the absence of XIST
and H3K27me3 is probably due to a phenomenon called
‘erosion’ that occurs in primed cells leading to partial X-
chromosome reactivation.[61,62] Based on these recent findings, it
is therefore important to define X-chromosome status in hPSCs
based on chromosome-specific expression of XIST, XACT and
other genes on the X-chromosome that do not escape silencing
by erosion. Taken together, although this suite of cell lines are
fascinating additions to the cellular toolbox, they do not align to
our current expectations of naïve or primed cells, and future
studies are required to further define their cell state and
functional properties.3.2. Identified Culture Conditions Capture Naïve hPSCs
With Preimplantation Embryo Hallmarks
Naïve hPSCs maintained in two further media formulations are
classified as being similar to human blastocysts based on several
molecular hallmarks. In the first, a screening approach
identified combinations of growth factors and small molecules
(termed 5i/L/A) that can induce and maintain naïve hPSCs
(Table 3).[26,37] Naïve hPSCs in these conditions exhibit one of the
closest similarities to the transcriptional and epigenetic profiles
of the human and primate preimplantation embryos.[22,25–28,60]
There are reported drawbacks associated with this method,
however, as long-term propagation in this formulation leads to
the irreversible loss of DNA methylation at the majority of
imprinted loci and to the misexpression of a subset of imprinted
genes.[26,27] Chromosomal instability is also frequently
reported.[26,63] In the second culture formulation, naïve hPSCs
are stabilised and propagated in a cocktail of low-dose 2i, LIF and© 2018 The Authors. BioEssays Published by WILEY Periodicals, Inc.
Table 3. Media compositions associated with the induction of naïve hPSCs.
Chemical inhibitor,
growth factor Target effect Hanna[47]
Gafni
NHSM[40]
Chan
3iL[48] Ware[50]
Theunissen
5iL/A(F)[26,37]
Takashima
t2iLþPKCi[35]
Chen
TL2i[49] Duggal[57] Qin[58]
Guo
t2iLþPKCi[34]
LIF LIF signaling @ @ @ @ @ @ @ @ @ @
PD0325901 MEK inhibition @ @ @ @ @ @ @ @ @ @
CHIR99021 GSK3 inhibition @ @ @ @ @ @ @ @
IM-12 GSK3 inhibition @
BIO GSK3 inhibition @
Gö6983 PKC inhibition @ @ @
Y-27632 ROCK inhibition @ @ @
WH-4-023 SRC inhibition @
SB590885 RAF inhibition @
SP600125 JNK inhibition @
SB203580 p38/MAPK inhibition @
TGFβ TGFβ signaling @
Activin A TGFβ signaling @
FGF FGF signaling @ @ @/X @
SAHA HDAC inhibition @
Sodium Butyrate HDAC inhibition @ @¥
Valproic Acid HDAC inhibition @¥
Dorsomorphin BMP inhibition @
Forskolin PKA inhibition @ @
Ascorbic Acid Demethylation @
Lysophosphatidic
acid
HIPPO inhibition @
Base media (1) (2) (3) (4) (1) (1) (1)(4)¥ (4) (1)(3) (1)
O2 level 20% 20 or 5% – 5% 5% – 5% 5% – 5%
Transgenes OCT4
KLF2
KLF4
NANOG
KLF2
STAT3
@, addition to media; , short-term induction or addition to the culture media; ¥, choice between two components; @/X, optional addition of a component; , not
documented.
Base media: (1) DMEM/F12: Neurobasal, N2B27; (2) KnockOut DMEM, N2B27; (3) TeSR1 (4) DMEM, 20% KSR.
www.advancedsciencenews.com www.bioessays-journal.coma PKC inhibitor (t2iLþPKCi) (Table 3).[35] This set of factors can
maintain naïve hPSCs that have been generated by NANOG and
KLF2–induced, KLF4–induced, or OCT4, KLF4, SOX2 and
MYC-induced reprogramming,[35,63,64] by transgene-free chemi-
cal resetting of primed hPSCs[34] and captured directly from
preimplantation human blastocysts.[41] Naïve hPSCsmaintained
in t2iLþPKCi exhibit many of the similarities to 5i/L/A naïve
hPSCs including a globally hypomethylated genome (Ta-
ble 1),[27,35,41,64] a close transcriptional alignment with preim-
plantation human and primate epiblast cells,[22,25,28,64] and, in a
proportion of cells, XIST-positive active X-chromosomes (Ta-
ble 2).[45,64] Many of the drawbacks are also shared with the
5i/L/A cells.[27,41] Curiously, a subset of naïve hPSC lines grown
in RSeT media, a commercial derivative of ‘naive human stem
cell medium’,[40] showed transcriptional similarly to t2iLþPKCi
cells, whereas other lines in the same RSeT conditions aligned
more closely to primed hPSCs.[64]
Taken together, recent reports on naïve hPSCs havemade great
advances in capturing cells that mimic many aspects of humanBioEssays 2018, 40, 1700239 1700239 (6 of 12)preimplantation epiblast cells. The resultant cell lines provide a
spectrum of cell states, with their associated advantages and
disadvantages, and further progress in optimising growth
conditions is expected to deliver more robust cell types.4. Developing Methods to Identify and Isolate
Naïve hPSCs
Monitoring the changes in cell state and the emergence of naïve
PSC populations are essential to optimise current protocols, and
will also provide valuable insights into the underlying molecular
mechanisms of human pluripotency. One of the predominant
approaches to generate naïve hPSCs is by reprogramming
primed hPSCs. However, the efficiency of this method is low and
variable between protocols, and often generates a heterogeneous
mixture of cells. Several of the early reports that document
deriving naïve hPSCs relied on obtaining homogeneous
populations through the continued passaging of cells under© 2018 The Authors. BioEssays Published by WILEY Periodicals, Inc.
www.advancedsciencenews.com www.bioessays-journal.comnaïve hPSC culture conditions. This bulk population approach is
dependent on the fully reprogrammed naïve PSCs having a
survival advantage when cultured in naïve conditions. Further-
more, this method may not be applicable where culture
conditions permit the survival of primed and differentiated cell
types, nor does it easily allow characterisation of the process due
to the high heterogeneity at intermediate stages of reprogram-
ming. Since then, several alternative approaches have been
devised to enrich for naïve PSC populations (Figure 3).4.1. Reporter Cell Lines can Cut Through Reprogramming
Heterogeneity
A key feature of naïve mPSCs and preimplantation mouse
epiblast cells is the preferential use of the Oct4 distal enhancer,
whereas primed EpiSCs and postimplantation epiblast cells
utilise a proximal enhancer.[16,65,66] To capitalise on this
regulatory switch defined in the mouse, several groups have
developed a reporter system to read out the activity of
endogenous human OCT4 expression coupled to GFP in cell
lines containing a deletion of the proximal enhancer (OCT4-
ΔPE-GFP). In a naive state, hPSCs activate alternative
enhancers, presumably including the conserved distal enhancer,
to drive OCT4–GFP expression,[37,40] which can be detected
using flow cytometry. An alternative reporter system termedPrimed hPSC
CD90
CD24CD57
SSEA4
Reporter system FACS
Bulk
 pas
sag
ing;
 clo
nal 
exp
ans
ion 
FACS for state-specific 
surface markers
Figure 3. Approaches to isolate naïve hPSCs during primed to naïve reprog
generate substantial cell heterogeneity during the process. Strategies to is
passaging and progressive selection, or clonal expansion of individual colo
coupled to the expression of fluorescent proteins provide a read out of charac
the cell-surface proteins expressed on naïve and primed hPSCs has identified
the isolation of naïve hPSCs using fluorescence-activated cell sorting (FACS
BioEssays 2018, 40, 1700239 1700239 (7 of 12)EOS-GFP has also been used to identify naïve hPSCs.[35]
EOS-GFP expression is driven from a mouse Early Transposon
promoter combined with mouse Oct4 enhancer elements that
contain OCT4 and SOX2 binding sites.[67] EOS-GFP expression
is gradually silenced in primed hPSCs, but reactivated upon
reprogramming to a naïve state, thereby providing a straightfor-
ward indication of pluripotent cell type. Adopting a similar
strategy, naïve-like hPSCs can be identified using a reporter for
the expression of the retrovirus HERVH, linked to a GFP
transgene.[68] Primed hPSCs with highHERVH-GFP expression
exhibit a reduction in gene expression of primed-associated
genes. When isolated using cell sorting,HERVH-GFP-high cells
adopt a naïve-like morphology compared to HERVH-GFP-low/
negative cells. Nonetheless, repeated re-sorting is required to
maintain a homogeneous population of naïve-like hPSCs.[69] The
cell phenotype is also unclear given that endogenous HERVH
transcription is associated with primed, and not with naïve,
hPSCs.[26]
Although reporter systems can provide a robust and simple
readout of cell state, they all have several caveats. First, there is a
requirement to genetically modify each cell line. Second, the
timing of reporter gene induction and the fidelity of the
expression are not always clear, and may not necessarily be
linked to cell state. Third, although it is assumed that the human
OCT4 enhancers are functionally similar to themouse, there has
not been an assessment of which regulatory elements areCD7
CD130
CD75
CD77
Naïve-like 
morphology
OCT4-ΔPE-GFP 
EOS-GFP 
HERVH-GFP 
Established naïve hPSCs
ramming. Primed to naïve reprogramming can be inefficient, and often
olate and derive defined populations of naïve hPSCs include: (1) Bulk
nies that exhibit a domed naïve-like morphology. (2) Reporter systems
teristics that are associated with naïve pluripotency. (3) Characterisation of
state-specific markers. Using antibodies specific to these markers enables
).
© 2018 The Authors. BioEssays Published by WILEY Periodicals, Inc.
www.advancedsciencenews.com www.bioessays-journal.compreferentially used to driveOCT4 expression in naïve hPSCs and
humanblastocysts.Newreporter-baseddesignswill require abetter
understanding of transcriptional dynamics and cell-type-specific
enhancer activity and interactivity in human development.[70]
Promising candidates could include a KLF17 reporter line as this
gene is activated at a late stage of primed to naïve hPSC
reprogramming,[71] or strategies to readout biallelic XIST expres-
sion as this property is present in all preimplantation human
epiblast cellsand inasubsetofnaïvehPSCs.[45,46]Therecentgenetic
modificationofhumanpreimplantationembryos also opensup the
possibility of experimentally testing the fidelity of reporter
constructs in human blastocysts.[72–76]4.2. Cell-Surface Proteins can Distinguish Between Human
Pluripotent States
Transgene-free methods to isolate naïve PSCs from a heteroge-
neous population would offer advantages over reporter-based
systems and manual isolation approaches. Until recently, there
were no known cell-surface markers that could define naïve
hPSCs. Three reports have each identified individual cell-surface
markers that are detected on primed, but not on naïve, hPSCs.
The first study showed that CD24 expression is higher in primed
hPSCs compared to naïve-like cells. Naïve-like hPSCs were
isolated by flow sorting using the pan-hPSC antigen TRA-1-60 in
combination with low expression of CD24.[77] Notably, greater
than ten passages under naïve culture conditions were required
before the CD24-low population arose for prospective cell
isolation, thereby limiting the ability to interrogate cells during
the reprogramming process. A second study examined the
expression of SSEA-4, a well-characterised marker of primed
hPSCs.[78] Pastor et al. reported heterogeneous expression of
SSEA-4 on naïve hPSCs cultured using 5i/L/A conditions.[27]
When comparing transcriptional profiles of SSEA-4-positive and
SSEA-4-negative populations, preimplantation epiblast-specific
genes were more highly expressed in the SSEA-4-negative
fraction. In light of this result, it would be interesting to re-
evaluate the expression pattern of SSEA-4 in the human
blastocyst to see whether epiblast cells show variable levels.[78]
A third report identified four antibodies (raised against GPR64,
CDH3, NLGN4X and PCDH1) that showed higher reactivity
against primed compared to 5i/L/FA naïve hPSCs.[79] Collec-
tively, these studies provide helpful markers to characterise
established naïve hPSCs lines. However, the lack of a known
positive marker for human naïve cells limited the ability to
unambiguously detect naïve hPSCs within a mixed population
including during reprogramming.4.3. A Panel of Cell-Surface Proteins can Detect Nascent
Naïve hPSCs During Reprogramming
Given the absence of robust methods to prospectively identify
naïve hPSCs without genetic modification, a study screened 486
cell-surface antibodies with the aim of identifying state-specific
cell-surface antigens.[71] A set of cell-surface markers were
detected uniquely in each cell state, and comprising of 58 primed
and 8 naïve-specific markers. A cohort of markers was validatedBioEssays 2018, 40, 1700239 1700239 (8 of 12)using several primed and naïve hPSCs lines. Moreover, the
presence of these markers was examined by immunofluorescent
microscopy in human blastocysts. Interestingly, four of the five
naïve-specific markers were detected, whereas all primed-
specific markers were absent, which is consistent with the
expected difference in developmental staging. Notably, however,
some of the naïve markers localised to epiblast and extraembry-
onic cells of the embryo, indicating that the proteins are not
necessarily restricted to pluripotent cells at this phase of
development.
A multiplexed panel of validated antibodies capable of
discriminating between naïve and primed hPSCs was assem-
bled. This panel included four naïve-specific antibodies (CD7,
CD77, CD75 and CD130) and three primed-specific antibodies
(CD24, CD57 and CD90). The panel could distinguish between
naïve and primed cells, track the dynamics of naïve  primed
interconversion, and isolate emerging naïve hPSCs from a
heterogeneous cell population during reprogramming. Nascent
naïve cells that express all four naïve markers and lack all primed
markers could be isolated 10 days into the resetting process. This
is an earlier time point than permitted by current, alternative
isolation strategies, and enabled the first investigation of
intermediate cell types during reprogramming. Interestingly,
the proportion of nascent hPSCs on day 10 was considerably
higher when using 5i/L/A (14%), compared to1% seen using
t2iLþPKCi conditions, suggesting that the reprogramming
process is amenable to further improvements. Flow-sorted
hPSCs formed compact and domed colonies upon plating in
naïve hPSC conditions, thereby providing a straightforward
approach to obtaining naïve hPSC lines.
More recently, a systematic comparison of naïve hPSC lines
grown under different conditions revealed a range of cell-surface
marker profiles, thereby moving towards developing immuno-
phenotyping as diagnostic for naïve cell types.[63,80] Notably, out of
a set of six antibodiesused, only one couldpositively identify naïve
hPSCs, and there was increased fluorescent intensity in naïve
hPSCs compared with primed cells. The antibody was raised
against the cell-adhesionmolecule F11R, and it will be interesting
to see if this expression difference could underlie the distinct
morphological differences between pluripotent cell types.
There are a number of advantages to using cell-surface
antibodies compared to alternative isolation strategies. First, live
naïve cells can be detected without the need for cell line
modification. Second, cell-surface markers provide a quantitative
and defined endpoint, allowing the efficiency of different resetting
protocols to be compared. Third, naïve cells can be isolated at an
earlier time point than permitted by alternative strategies. For the
first time, this enables the timing and order of molecular changes
that occur during resetting to be examined. Cell-surface markers
also have several drawbacks. First, the approach is limited by
antibody availability and quality. Second, there are some
experimental contexts when cell-surface markers are less applica-
ble, such as during the derivation of naïve hPSCs directly from
embryos. Third, themarkers themselves do not necessarily have a
functional role in human pluripotency. Further work is needed to
examine this, although several naïve-specific markers such as
CD75 andCD77 are uncharacterised glycoproteins andwill not be
straightforward to study. Development of neutralising antibodies
against their epitopes would provide one approach to investigate© 2018 The Authors. BioEssays Published by WILEY Periodicals, Inc.
www.advancedsciencenews.com www.bioessays-journal.comtheir function. It may also be possible to use antibody-mediated
immunoprecipitation in combination with mass spectrometry to
identify proteins that interact with the glycoproteins, whichmight
provide insight into their target pathways. Another line of future
research could focus on trying to identify a single, cell-surface
marker that can positively discriminate naïve hPSCs. This search
might require generating new antibodies potentially guided by
proteomic studies to catalogue shared and state-specific cell-
surface proteins.5. Current Applications and Challenges in
Naïve hPSC Biology
The capture of naïve hPSCs has opened up new research
directions by enabling the investigation and manipulation of
human preimplantation-like cells. Exciting examples so far
include the functional testing of preimplantation transcription
factors,[35] the elucidation of processes that control X-chromo-
some dosage compensation,[45,60] the connection between
transcriptional changes and tissue architecture during pluripo-
tent state transition,[81] and chromosome organisation in the
context of gene regulatory interactions.[36] Naïve hPSCs also
provide a unique cellular model to examine the regulation of
transposable elements, which are highly species- and develop-
mental-stage specific.[26,82] The next few years will continue to
yield much needed insights into the regulation of pluripotent
states, and naïve hPSCs will provide a valuable and tractable
model to interrogate the associated mechanisms.5.1. Uncertainties About Naïve hPSCs as a Starting Point
for Cell Differentiation
It is also important to discuss the limitations of naïve hPSCs. In
our opinion, for example, there are few obvious advantages in
using naïve hPSCs as the starting point for most cell
differentiation experiments, especially when primed hPSCs
differentiate effectively and have been tailored by robust
protocols. Recent studies have shown that 5i/L/A and t2iLþ
PKCi naïve hPSCs differentiate poorly into somatic tissues.[63,83]
This is perhaps not unexpected, given that naïve hPSCs need to
first break the strong signaling inhibition that holds them in a
naïve state, before transitioning towards a primed state and
further differentiation. Similar events may also occur during
embryogenesis, where preimplantation epiblast cells transition
to a postimplantation state before the onset of gastrulation.
As a counterpoint, proposals have been made that naïve
hPSCs could offer a uniform and less restricted starting point
for differentiation experiments, potentially due to the erasure of
the lineage-biases or X-chromosome variability that have been
detected in primed cells. At the moment, however, there is little
evidence to support this proposition. Indeed, the use of current
naïve hPSCs as a starting point would come at the cost of
misregulated imprinted genes and the increased probably of
acquiring genetic changes, which would introduce substantial
variability into the differentiation outcomes. Potentially cell
states and growth conditions could be identified that reduce the
intrinsic biases of primed hPSC lines without transitioningBioEssays 2018, 40, 1700239 1700239 (9 of 12)fully to a naïve state and the adoption of associated instabilities.
For example, a recent study described the derivation of
‘Advanced’ mPSCs, which exhibit a combination of properties
that is distinct from naïve and primed cells including
DNA hypermethylation and high developmental potency in
chimeras.[84]
There are two specific examples in which naïve hPSCs might
offer an advantageous starting point for differentiation experi-
ments. The first is for germ cell differentiation. Mouse PSCs that
have been induced transiently to a naïve state undergo effective
germ cell differentiation.[85] Initial indications using hPSCs look
promising but are too early to tell.[86,87] The second is whether
naïve hPSCs can form extraembryonic cell types. This has not
been examined directly, although curiously, the expression of
several trophectoderm-associated genes are detected in naïve
hPSCs and not in primed hPSCs, and on a global scale some
naïve hPSC lines show high transcriptional overlap with morula
stages of development.[26] Could naïve hPSCs harbour a
transcriptional ‘memory’ of cells before epiblast segregation
and retain some extraembryonic differentiation capacity? As
lineage segregation in the human embryo is specified at a
relatively late stage of development[33] then this scenario is
possible and further experiments are warranted. Particularly
useful in this context are on-going efforts to project naïve hPSCs
on to a developmental map to see how closely the cells grown in
various conditions align to embryo stage and cell type.[28]5.2. Gene Regulatory Networks and Signaling Pathways are
Poorly Understood in Naïve hPSCs
Other major knowledge gaps include the definition of gene
regulatory networks that govern naïve pluripotency in humans,
andanunderstandingofhow thenetworks reformupon transition
to a primed pluripotent state. Differences in enhancer rewiring
have been detected between naïve and primed hPSCs, and often
correspond to a transcriptional change for the set of genes
examined.[36] Expanding this by integrating with data sets of
chromatin accessibility, transcription factor occupancy, and high-
resolution DNA interactions will reveal a more precise view of
regulatory control in human naïve pluripotency. This information
could also feed into the design of a newgeneration of sensitive and
accurate reporter systems for human pluripotent cells.
In addition, little is known about the signaling requirements
of naïve hPSCs. The signaling pathways targeted for inhibition
and activation, and their downstream effects, are largely
unexplored. Naïve hPSC growth conditions will be optimised
as signaling pathways are tested. Progress in this area may
benefit from moving away from expectations based on mouse,
and instead use unbiased approaches, such as chemical and
genetic screens in combination with evidence of signal pathway
activity from proteomics and phosphoproteomics. Lastly, a
consensus on how to phenotypically define pluripotent states
needs to be reached, and a recent article has argued that the
reliance on a narrow set of readouts, such as the OCT4-ΔPE-GFP
reporter, should be expanded to include additional state-specific
markers.[21] Collectively, these studies will also raise interesting
new hypotheses about how signaling pathways and gene
regulatory networks operate in the early stages of human© 2018 The Authors. BioEssays Published by WILEY Periodicals, Inc.
www.advancedsciencenews.com www.bioessays-journal.comembryogenesis, which can be tested experimentally in blasto-
cysts to provide new insights into human development.6. Conclusions and Outlook
A dozen or so reports have now described growth conditions
that can lead to human cells acquiring characteristics of the
preimplantation-stage embryo. These publications have
resulted in a spectrum of hPSCs with variable properties that
have collectively, and perhaps confusingly, been termed ‘naïve’.
Efforts to reach consensus on how to define bona fide naïve
hPSCs using measurable and unambiguous properties are
underway and will hopefully be adopted widely by the field.
Carefully defining hPSC states allows the informed selection of
the most appropriate set of methods for cell growth and
differentiation, and is important for interpreting and replicating
experimental outcomes. A range in cell phenotypes could be
advantageous to researchers as certaingrowthconditionsmightbe
better at mimicking preimplantation biology, and perhaps others
for germ cell differentiation. The composition of each media
formulationwill be further refined andoptimised, andresearchers
and reagent suppliers will need to be responsive to the changing
conditions. In this regard, defining the activity and necessity of
signaling pathways in naïve hPSCs is a priority for the field. An
emerging picture is that achieving the optimum level of MEK
inhibition is critical for propagatingstablenaïvemPSCs, and itwill
be interesting to see if there are similar requirements in human
cells and how this might crosstalk with other signaling pathways.
Advances made in understanding naïve hPSCs will have
important significance in a range of biological contexts. For
example, studying how the transitions between naïve and primed
pluripotent states are controlled will provide new insights into
defining how cells change state in other systems, including
concepts such as whether there are multiple routes of cell state
change, and exploring the nature of intermediate transition
phases. Another example includes characterising the epigenomic
events that occur upon human pluripotent state transitions, such
as X-chromosome reactivation and global DNA hypomethylation.
Thesemajor events occur in other cellular transitions, particularly
in theonsetofdisease, andmaysharesimilarpathwaysand targets.Abbreviations
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